Systematic reviews and meta-analysesHealth-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review
Keywords
Abbreviations used in this paper
Cited by (0)
This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e50. Learning Objective–Upon completion of this activity, successful learners will be able to interpret the current state of the published literature related to health-related quality of life and economic burden in patients with eosinophilic esophagitis.
Conflicts of interest These authors disclose the following: Vincent Mukkada has received research funding from the National Institutes of Health Patient-Centered Outcomes Research Institute, is participating in a Shire budesonide study, and is a consultant for Shire; Gary W. Falk has received research funding from Shire, Regeneron, and Celgene, and is a consultant for Adare Pharmaceuticals; Christian S. Eichinger is an employee of PharmaGenesis London, which has received funding from Shire; Denise King was an employee of Oxford PharmaGenesis at the time of the study, which has received funding from Shire; and Lora Todorova is an employee of Shire. The remaining author discloses no conflicts.
Funding Medical writing support was provided by PharmaGenesis London, UK, funded by Shire International GmbH.